Dr Jean Abraham

Cambridge University Hospitals NHS Foundation Trust

University departments
Department of Oncology
NHS or other affiliations
Breast Unit

Position: Academic Honorary Consultant in Medical Oncology
Personal home page: http://www.cuh.org.uk/cms/addenbrookes-hospital/services/cambridge-breast-unit/meet-team/oncologists/dr-jean-abraham
Email:   ja344@medschl.cam.ac.uk

PubMed journal articles - click here

Dr Jean Abraham is pleased to consider applications from prospective PhD students.

Research description

-

Research Programme
Breast Cancer
Methods and technologies
Clinical trials
DNA sequencing
Epidemiology
Genomics
Tumour type interests
Breast
ja344
Recent publications:
 Retrieving latest data from feed...

Symplectic Elements feed provided by Research Information, University of Cambridge


Key publications

1. Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier A-L, Abraham J, Thomas J, Provenzano E, Hughes-Davies L, McAdam K, Chan S, Ahmad R, Hickish T, Houston S, Rea D, Bartlett J, Caldas C, Cameron D, Hayward L. ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response”. ASCO abstract 1014

Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier A-L, Abraham J, Thomas J, Provenzano E, Hughes-Davies L, McAdam K, Chan S, Ahmad R, Hickish T, Houston S, Rea D, Bartlett J, Caldas C, Cameron D, Hayward L. ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy for patients with HER2-negative early breast cancer. SABCS 2014 abstract PD2-3.

HM Earl, Suet-Feung Chin, Mark Dunning, Mahesh Iddawela, OscarRueda, Roslin Russell, Linda Jones, A-L Vallier, Luke Hughes-Davies, Jean Abraham,Steve Chan, Anthony Skene, Kim Benstead, Christopher J. Gallagher, Philip Murray,Nicholas Murray, Diana Ritchie, Janet A. Dunn, Louise Hiller, Carlos Caldas, NeotAnGo Investigators;Neo-tAnGo science: A translational study of PAM 50 sub-typing in sequential fresh tissue samples during neoadjuvant chemotherapy. Abstract #116857, ASCO 2013

Abraham JE, Guo Q, Earl HM, Pharoah P.D.P, Caldas C. Detection of pharmacokinetic candidate genes associated with taxane related neurotoxicity by genome wide association studies. NCRI Conference 2012.

Abraham JE, Rueda O, Chin SF, Guo Q, Harrington P, Earl HM, Pharoah P.D.P, Caldas C. Pharmacogenetics of breast cancer chemotherapy - copy number variation and risk of chemotherapy-related infection. San Antonio Breast Cancer Conference 2012.

Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C, Luccarini C, Shah M, Ingle S, Greenberg D, Earl HM, Dunning AM,. Pharoah P.D.P, Caldas C. CYP2D6 gene variants: Association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. NCRI Conference 2010.

Guo Q, Abraham JE, Caldas C, Curtis C, Earl HM, Tyrer J, Garcia-Closas M, Rahman N, Eccles D, Evans G, Easton D, Hall P, Kraft P, Pharoah P. A genome-wide association study of breast cancer prognosis. NCRI Conference 2010.

Abraham J, Maranian M, Dunning A, Earl HM, Caldas C. Successful paired blood and saliva DNA in high throughput genotyping and genome-wide association studies. Poster presentation NCRI Conference 2009.

H. M. Earl, A. Vallier, L. Hiller, N. Fenwick, M. Iddawela, Abraham J, L. Hughes-Davies, E. Provenzano, K. McAdam, T. Hickish, C. Caldas. Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR). Abstract #522, ASCO 2009

Abraham J, Maranian M, Driver K, Shah M, Dunning A, Earl HM, Pharoah P. Caldas C. CYP2D6 variants and breast cancer susceptibility. NCRI Conference 2008.

Abraham J, Maranian M, Driver K, Shah M, Dunning A, Earl HM, Pharoah P, Caldas C. CYP2D6 variants and breast cancer survival in tamoxifen treated patients. San Antonio Breast Cancer Conference 2008

Abraham J, Harrington P, Driver K, Tyrer J, Dunning A, Pharoah P. Tagging SNPs in the Prostaglandin Pathway and Breast Cancer Susceptibility. NCRI Conference 2007.

Abraham JE, Earl HM, Poole CJ, Dunning A, Pharoah P, Ponder B, Caldas C. PG-SNPS: A Pharmacogenetic Study in Early Breast Cancer Chemotherapy. NCRI Conference 2005.

Pratt J Palmer C, Basu B, Abraham JE, Biswas S, Iddawela M, Brenton J, Earl HM, A study to evaluate the use of Ca125 in ovarian cancer (EOC) follow-up (FU). A change in practise led by patients’ preference. British Journal of Cancer; 88(1): p183. NCRI Conference 2003.

Pratt J, Basu B, Palmer C, Abraham JE, Biswas S, Iddawela M, Brenton J, Earl HM, van der Burgh schedule (VDBS) in relapsed ovarian cancer (REOC): A tolerability study in Cambridge Gynae-Oncology Centre. British Journal of Cancer; 88(1): p129. NCRI Conference 2003.

Basu B, Abraham JE, Bulusu V, Grant K, Corcoran M, Shaw J, Harris R, Corrie P, Wilson C. Oral Capecitabine in Metastatic Colorectal Cancer. British Journal of Cancer; 86; Suppl. S47. NCRI Conference 2002.

Abraham JE, Roberts L, Benson R, Earl HM. Waiting times Audit – Organisation of Oncology Clinics - Have We Got It Right? British Journal of Cancer; 86; Suppl.1 S71. NCRI Conference 2002.

*Abraham JE, Coles C, Burnet N, Earl HM. Concurrent conformal radiotherapy and chemotherapy in patients with primitive neuroendocrine tumours, Ewings sarcoma and leiomyosarcoma. Sarcoma; Vol; 5; No.3 p183. European Organisation for Research and Treatment of Cancer (EORTC); Soft Tissue and Bone Sarcoma Meeting 2001: Aarhus, Denmark.

Abraham JE, McAdam K, Wilson C, Earl HM. Vinorelbine and Cisplatin phase II pilot study in patients with Metastatic Breast Cancer. British Journal of Cancer; 85; No.1 p51. NCRI Conference 2001.

(* denotes oral presentation)